Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal(UNSW Sydney), David R. Matthews(Manchester College), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Dick de Zeeuw(University Medical Center Groningen), Gordon Law(The George Institute for Global Health), Greg Fulcher(The George Institute for Global Health), Ngozi Erondu(The George Institute for Global Health), Mehul Desai(Enable Ireland), Wayne Shaw(The George Institute for Global Health), Vlado Perkovic(New South Wales Department of Health)
New England Journal of Medicine
June 12, 2017
10.1056/nejmoa1611925
Cited by 7,749

Related Papers

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k